Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2024-04-02 00:00:00 ET · period of report 2024-03-30 · accession 0001140361-24-017373 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-04-02 | 2024-03-30 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | — | +390.6K | 1.38M | +39% | — |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Gline Matthew | CEO, Dir | F - Tax | $10.54 | -216.0K | 1.16M | -16% | -$2.28M |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | $6.40 | -994.4K | 0 | -100% | -$6.36M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-03-30 | M | A | 390,579 | — | 1,380,642 | D | — | — | (F2) On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). |
| 2 | Common | Common Shares | 2024-03-30 | F | D | 215,991 | $10.54 | 1,164,651 | D | — | — | |
| 3 | Derivative | Capped Value Appreciation Rights | 2024-03-30 | M | D | 994,373 | $6.40 | 0 | D | — · — to 2026-03-31 | 390,579 Common Shares | (F4) This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. (F2) On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). |